How can we fight back against the spread of health misinformation?
Read more about what health communicators and pharmaceutical companies can do.
Optimising patient journeys to inform strategy and improve patient outcomes
Learn how patient journeys can be used more effectively to improve strategic planning, stakeholder engagement, and patient outcomes.
Meetings that matter: designing events for impact, integrity, and innovation
Find out how compliance, innovation, and new engagement strategies are reshaping medical meetings in our summary of The Future of Healthcare Meetings 2024.
New year, new ABPI Code
The 2024 ABPI Code of Practice is now in force: find out more about the new option to share prescribing information via QR code.
[VIDEO] The 2024 ABPI Code of Practice – key takeaways for MedComms
Jayne Packham highlights key updates to the 2024 ABPI Code of Practice.
Discovering AI and the future of Medical Affairs: summary of Day 2 of the MAPS 2024 EMEA Annual Meeting
Missed the meeting? Read our report to get up to speed!
Discovering AI and the future of Medical Affairs: summary of Day 1 of the MAPS 2024 EMEA Annual Meeting
Missed the meeting? Read our report to get up to speed!
Expanding horizons: how ISMPP maximises reach for small pharma and biotech professionals
Find out about the benefits of ISMPP membership for professionals in small pharma and biotech companies.
Challenging the status quo in medical communications: an interview with James Dathan
James Dathan shares his perspectives on why we need to change standard practices and adopt a more creative, innovative approach to medical communications.
Innovation in medical communications: an interview with Catherine Skobe
Catherine Skobe shares her insights on innovation in medical communications including creative approaches to increasing patient engagement and involvement in scientific publications.
To tweet or not to tweet: social media guidance to help pharmaceutical companies adhere to the ABPI Code of Practice
Read about new guidance from the PMCPA that aims to ensure the social media activities of pharmaceutical companies stay within the law.
An interview with Valérie Philippon: beyond clinical trial data
Valérie Philippon shares her perspectives on the value of including data beyond those generated in clinical trials in publication plans.
[VIDEO] Managing the tricky planning and collection of meeting data
Braydon McCormick and Mark Handforth discuss collecting meaningful data about meetings.
[VIDEO] From web 1.0 to social communities: understanding the evolution of HCP engagement
Antonia Trent and James Atherton discuss recent changes in the HCP engagement landscape.
Quantifying authorship in clinical trial publications – a new algorithm
Learn about a new decision support tool developed to supplement the ICMJE criteria and GPP3 guidelines.
Shedding light on industry influence over healthcare
New study maps ties between the medical product industry and healthcare ecosystem, exposing regulatory and transparency issues.